Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.33 USD | -0.13% | -1.09% | +16.47% |
Apr. 19 | Nephron Research Raises Boston Scientific's Price Target to $80 From $75 | MT |
Apr. 17 | FDA classifies recall of Boston Scientific device as 'most serious' | RE |
Evolution of the average Target Price on Boston Scientific Corporation
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Boston Scientific Corporation
Nephron Research | |
Baird | |
Truist Securities | |
BTIG | |
RBC Capital Markets | |
Argus | |
Citigroup | |
TD Cowen | |
Raymond James | |
Jefferies & Co. | |
JPMorgan Chase | |
Mizuho Securities | |
Wells Fargo Securities | |
Canaccord Genuity | |
Needham & Co. | |
Oppenheimer | |
UBS | |
Morgan Stanley | |
Stifel Nicolaus | |
Bernstein | |
Barclays | |
Evercore ISI | |
Piper Sandler | |
CL King | |
Deutsche Bank Securities | |
Goldman Sachs | |
Wolfe Research | |
BofA Securities | |
SVB Leerink | |
Credit Suisse | |
Atlantic Equities |
EPS Revisions
- Stock Market
- Equities
- BSX Stock
- Consensus Boston Scientific Corporation